Dr. Sereti on Addressing an Unmet Need With NOV202/Olaparib in BRCA1/2-Mutated Prostate Cancer

Evangelia Sereti, MSc, PhD, a postdoctoral fellow at Urological Cancer, Malmö, Division of Translational Cancer Research, Lund University Cancer Centre, discusses the unmet need addressed with the addition of NOV202 to olaparib (Lynparza) in BRCA1/2-mutated prostate cancer.

Preclinical findings, which were presented during the 2021 EAU Congress, aimed to evaluate whether NOV202, a vascular-disrupting agent, could increase the anticancer efficacy of the PARP inhibitor olaparib in prostate cancer–based xerograph mouse models with BRCA1/2 mutations, Sereti says.

This research addresses an urgent clinical need, which is to develop novel, combinational therapeutic strategies that can improve the efficacy observed with single-agent PARP inhibitors, prevent or overcome resistance to PARP inhibitors, and expand the population that may benefit from treatment with PARP inhibitors, Sereti concludes.